BCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos
|
|
- Mavis Reynolds
- 5 years ago
- Views:
Transcription
1 BCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos
2 Ph like ALL BCR ABL1 like acute lymphoblastic leukemia (ALL) is a recently identified B cell ALL (B ALL) subtype with poor outcome that exhibits a gene expression profile similar to BCR ABL1 positive ALL but lacks the BCR ABL1 fusion protein.
3 Istorija Gene expression profiling of ALL Eng Juh Yeoh et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling Gene expression profile similar to BCR ABL January. Mullighan, C.G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. First Ph like February. Den Boer, M.L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome wide classification study.
4
5
6 One of the most surprising observations from this study was the identification remarkable difference of the individual leukemia subtypes. HG_U95Av2 oligonucleotide array (Affymetrix) transkriptų
7 Istorija Gene expression profiling of ALL Eng Juh Yeoh et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling Gene expression profile similar to BCR ABL January. Mullighan, C.G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. First Ph like February. Den Boer, M.L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome wide classification study.
8 2009
9 Despite best current therapy, up to 20% of pediatric patients with acute lymphoblastic leukemia (ALL) have a relapse. Recent genome wide analyses have identified a high frequency of DNA copy number abnormalities in ALL, but the prognostic implications of these abnormalities have not been defined. Genetic alteration of IKZF1 is associated with a very poor outcome in B cell progenitor ALL....deletion of IKZF1 is frequent in BCR ABL1 ALL, suggests that IKAROS abnormalities are important in the pathogenesis of both BCR ABL1 positive B cell progenitor ALL and BCR ABL1 negative ALL that is associated with a poor outcome. The gene expression signatures of patients with poor outcome (IKZF1 deleted) ALL in the original and validation cohorts were very similar to each other and to the signature of BCR ABL1 positive ALL, a subtype of ALL in which IKZF1 deletion is very common. Since BCR ABL1 ALL has a poor prognosis, these findings suggest that the deletion of IKZF1 is a key determinant of a poor outcome both in patients with BCR ABL1 positive and patients with BCR ABL1 negative disease transkriptų (Affymetrix)
10 25% of precursor B ALL cases are genetically unclassified and have intermediate prognosis. We constructed a classifier based on gene expression in 190 children with newly diagnosed ALL. Classifying gene probe sets revealed a new ALL subtype, the underlying genetic abnormalities of which were characterised by comparative genomic hybridisation arrays and molecular cytogenetics. The prognosis of BCR ABL1 like disease was similar to that of BCR ABL1 positive ALL. 36 (82%) of the patients with BCR ABL1 like disease had deletions in genes involved in B cell development, including IKZF1, TCF3, EBF1, PAX5, and VPREB transkriptų (Affymetrix)
11 Istorija Gene expression profiling of ALL Eng Juh Yeoh et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling Gene expression profile similar to BCR ABL January. Mullighan, C.G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. First Ph like February. Den Boer, M.L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome wide classification study. Transcriptome and whole genome sequencing on 15 cases of Ph like ALL Roberts KG. et al. Genetic alterations activating kinase and cytokine receptor signaling in high risk acute lymphoblastic leukemia. A total of 154 patients with Ph like ALL underwent detailed genomic analysis Roberts KG, et al. Targetable Kinase Activating Lesions in Ph like Acute Lymphoblastic Leukemia
12 We performed transcriptome and whole genome sequencing from 15 patients with Phlike ALL. Strikingly, we identified alteration of genes encoding cytokine receptors and regulators of tyrosine kinase signaling in all 15 cases studied.
13
14 We next performed recurrence screening of extended cohorts of high risk B ALL to determine the frequency of these genetic alterations. 231 cases, 40 Ph like (14%) Twenty five cases (8.8%) had high CRLF2 expression, 19 of which were Ph like and 6 non Ph like. JAK mutations were present in ten cases with high CRLF2 expression, all of which were Ph like. The EBF1 PDGFRB fusion was detected in three Ph like patients (8% of Ph like ALL). Two cases with NUP214 ABL1 rearrangement. No ABL1, JAK2, or PDGFRB rearrangements were identified in the MPN, CMML, and AML cohorts and have not been detected in other childhood B ALL subtypes studied by WGS and mrna seq, indicating these genetic lesions are highly enriched in the Ph like subtype. IL7R mutations in 5/40 Ph like patients (12,5%). One Ph like case with SH2B3 mutation. Four Ph like cases with FLT3 mutations.
15 Istorija Gene expression profiling of ALL Eng Juh Yeoh et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling Gene expression profile similar to BCR ABL January. Mullighan, C.G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. First Ph like February. Den Boer, M.L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome wide classification study. Transcriptome and whole genome sequencing on 15 cases of Ph like ALL Roberts KG. et al. Genetic alterations activating kinase and cytokine receptor signaling in high risk acute lymphoblastic leukemia. A total of 154 patients with Ph like ALL underwent detailed genomic analysis Roberts KG, et al. Targetable Kinase Activating Lesions in Ph like Acute Lymphoblastic Leukemia
16 We performed genomic profiling of 1725 patients with precursor B cell ALL and detailed genomic analysis of 154 patients with Ph like ALL. Transcriptome sequencing, whole genome sequencing, and whole exome sequencing.
17 Genomic alterations activating kinase signaling were identified in 91% of patients with Ph like. Subgroups: ABL1 fusions (12.6 %), rearrangements of EPOR or JAK2 (3.9%), rearrangements of CRLF2 (49.7%); Other JAK STAT (IL7R, FLT3, SH2B3, JAK1, JAK3, TYK2, IL2RB) (12.6%) Ras pathway mutations (4.3%) uncommon fusions (e.g., involving NTRK3 or DGKH) (0.9%) no kinase alterations (4.8%) material for analysis was not available (3.9%). Notably, ABL class rearrangements were more common among children, and JAK2 rearrangements were more frequent among young adults
18 123 of 264 patients with Ph like ALL had high CRLF2 expression, with the frequency ranging from 24% among children with standard risk ALL to 60% among adolescents with ALL (among patients with high CRLF2 expression, P2RY8 CRLF2 in 45 patients and IGH CRLF2 in 61 patients). Sixty eight patients (55%) with CRLF2 rearrangement had Janus kinase mutations, most commonly in JAK2. We found additional alterations activating JAK STAT in 5 of 11 patients who had CRLF2 rearrangement but no JAK mutations; these alterations included IL7R mutations (4 patients), an FLT3 mutation (1 patient), and a deletion of SH2B3. Sequence mutations and focal deletions activating JAK STAT signaling, including in IL7R, FLT3, SH2B3, JAK1, and JAK3, were identified in 31 patients without CRLF2 rearrangement or other kinase fusions. Fifteen patients had alterations in the Ras pathway only, including NRAS, KRAS, PTPN11, NF1, and BRAF.
19
20 Acute lymphoblastic leukemia (ALL), a cancer of white blood cells, is the most common malignancy in children and remains the most frequent cause of cancer death in the US among persons younger than 20 years old. The prevalence of Ph like ALL increases with age and that the older age groups, adolescents and young adults, have inferior outcomes (Table 1). Among all age groups studied, Ph like ALL was an independent adverse prognostic factor (NHI data).
21
22 ABL1 fusions (12.6 %), rearrangements of EPOR or JAK2 (3.9%), rearrangements of CRLF2 (49.7%); Other JAK STAT (IL7R, FLT3, SH2B3, JAK1, JAK3, TYK2, IL2RB) (12.6%) Ras pathway mutations (4.3%) uncommon fusions (e.g., involving NTRK3 or DGKH) (0.9%) no kinase alterations (4.8%) material for analysis was not available (3.9%).
23 132 adult ALL patients (age years, median 54 years) (lacking of BCR ABL1, MLL AF4 and E2A PBX1) GEP (Roberts et al., 2014) FISH targeting ABL1, ABL2, CSF1R, PDGFRB and JAK2 Fusion specific RT PCR for the identification of the respective ABLandJAK fusion partner Quantitave RT PCR for CRLF2 overexpression 13/132 Ph like pts 11/132 Ph like pts 4/132 with rearrangements ABL1 (SNX2 ABL1; n=1), and PDGFRB (EBF1 PDGFRB; n=3) 15 Ph like (11 overexp. CRLF2 + 4 ABL, PDGFRB fusions) combination of quantitative RT PCR, FISH and fusion specific RT PCR identified 15 cases (12%) compared to 13 cases (10%) identified by GEP with Ph like ALL. 7 pts IGH CRFL rearranged (FISH) 2 pts NRAS+ 8 pts JAK2+ 13 pts were assigned to the Ph like subset by both approaches, 2 patients by alternative approuches. while no patient was identified by GEP only. IKZF1 deletions in 12/15 patients. 1) Analysis of CRLF2 expression. 2) FISH targeting ABL and JAK pathway activating fusions involving the genes ABL1, ABL2, CSF1R, PDGFRB and JAK2. 3) Fusion specific RT PCR for the identification of the respective ABL and JAK fusion partner and sensitive MRD monitoring.
24 1) Analysis of CRLF2 expression. 2) FISH targeting ABL and JAK pathway activating fusions involving the genes ABL1, ABL2, CSF1R, PDGFRB and JAK2. 3) Fusion specific RT PCR for the identification of the respective ABL and JAK fusion partner and sensitive MRD monitoring.
25
26 Here we report the development and validation of a robust gene expression classifier that can prospectively identify Ph like ALL patients for therapeutic intervention. Affymetrix U133_Plus_2.0 The 15 gene LDA classifier was able to predict Ph or Ph like ALL in the test set with a high degree of sensitivity (93.0%) and specificity (89.7%). 15 of the 38 genes (IGJ, SPATS2L, MUC4, CRLF2, CA6, NRXN3, BMPR1B, GPR110, CHN2, SEMA6A, PON2, SLC2A5, S100Z, TP53INP1, IFITM1). We have developed and validated a highly robust gene expression classifier for the prospective identification of Ph like ALL. Rapidly screened patients will then undergo targeted sequencing to confirm the presence of specific genomic lesions.
27
28 There are significant differences in 5 year eventfree survival, with JAK2/EPOR rearranged cases (26.1±8.5) and CRLF2 rearranged JAK2 mutant cases (38.8±7.0) having a poor prognosis. Whilst cases harboring Other JAK STAT (68.3±9.9) and Ras pathway only alterations (85.7±11.5) have a more favorable outcome.
29 IKZF1 deletion Genetic alterations of IKZF1 influence the transcriptome of both Ph+ ALL and Ph ALL with a poor outcome. Mullighan et al The association between IKZF1 status and outcome was independent of age, leukocyte count at presentation, cytogenetic subtype; this indicates that detection of IKZF1 alterations at diagnosis might be useful in identifying patients with a high risk of treatment failure. Since BCR ABL1 ALL has a poor prognosis, these findings suggest that the deletions of IKZF1 is a key determinant of a poor outcome both in patients with BCRABL1 positive and patients with BCR ABL1 negative disease.
30
31 IKZF1 alterations were more common in patients with Ph like ALL who had kinase fusions (140 of 180 [78%]) than in those with a sequence mutation (14 of 43 [33%], P<0.001). Furthermore, patients with Ph like ALL who had an IKZF1 alteration had inferior median (±SD) 5 year event free survival, as compared with patients who had Ph like ALL without an IKZF1 alteration;
32
33 We performed a comprehensive analysis of the impact of IKZF1 del in a large cohort of children (n=1223) with BCR ABL1 negative BCP ALL treated in the EORTC CLG trial Patients with IKZF1 del had a lower 8 year event free survival (EFS, 67.7% versus 86.5%; hazard ratio (HR)=2.41; 95%confidence interval (CI)= ; P<0.001). Thus, IKZF1 del retains independent prognostic significance in the context of current risk adapted protocols.
34 IKZF1 positive IKZF1 positive IKZF1 positive IKZF1 positive V.Jodzevičiūtė E.Rožėnas K.Kosonia A.Malūkas BCR ABL1 positive BCR ABL1 positive BCR ABL1 negative BCR ABL1 negative, E2A positive Ph like?
35 ASH 2015 naujienos: adult ALL
36 The prevalence of Ph like ALL increases with age and accounts for over 25% of patients with B progenitor ALL between the ages of years. However, the frequency, outcome and genetic basis of Ph like ALL in adults over the age of 39 is unknown. 692 adults with B ALL. Ph like ALL comprised 26% of patients between years of age and 20% of patients aged Similar to previous reports, 99 of 186 (53%) of patients with Ph like ALL had high expression of CRLF2. Of 75 cases tested, 56 harbored IGH CRLF2 and 19 P2RY8 CRLF2. Of the 87 Ph like ALL patients with low CRLF2 expression, we identified rearrangements involving tyrosine kinase or cytokine receptor genes in 45 patients: ABL1 (n=5 patients), ABL2 (n=7), CSF1R (n=1), EPOR (n=8), JAK2 (n=18),pdgfra(n=1), PDGFRB (n=2), PTK2B (n=1) and TYK2 (n=2). Nine of these 45 fusions have not previously been identified in Ph like ALL. Exome sequencing is being performed on cases that do not harbor a kinase fusion by RNA seq analysis.
37 The WES analysis of the 41 Ph negative cases identified 735 point mutations and 25 mutations that occur in splicing sites in 651 genes. The average number of somatic coding mutations was 17 per case (range 1 47). Many studies found that deletion of CDKN2 was associated with poor prognosis in ALL,and CDKN2 deletion also as a frequent cytogenetic aberration in Ph+ ALL patients. Here we study about the prognostic significance of the CDKN2 in Ph+ ALL in TKIs era. 135 Ph+ patients (98 denovo and 37 relapsed cases). The prevalence of CDKN2 deletions in all study population was 27.4%(37/135). Deletions of CDKN2 were significantly associated with poor outcomes including decreased overall survival (OS) (P<0.001), lower disease free survival (DFS) (P<0.001), and increased cumulative incidence of relapse (P=0.003). Deletion of CDKN2 by I FISH is a frequent event in Ph positive ALL, and frequently acquired during leukemia progression and are a poor prognostic marker of long term outcomes even though treated by adding dasatinib. We also found CDKN2 deletion patients had higher CD20 expression, this group patients may be benefit from rituximab.
38 We analyzed 70 adult B ALL patients (median age 45 years, range 18 83) Deletions:CDKN2A (48.6%), IKZF1 (40%), PAX5 (24.2%), BTG1 (17.1%), ETV6(15.7%), BTLA (14.3%), RB1 (5.7%), EBF1 (5. 7%), LEF1 (2.9%), and TCF3 (2.9%). Gains: ERG (30%), ETS2 (21.4%), MYB (20%), UBASH3B (20%), PTEN (20%), PRKCH (18.6%), CDK6 (17.1%), andetv6 (12.9%). 27 samples obtained at the time of relapse were screened for the recurrent CNAs identified in the diagnostic samples. Incidence of CNAs at these genes was lower in the relapse cohort than the initial diagnostic cohort, although there was a higher frequency of CNAs at PAX5, BTLA, ETS2, RB1, LEF1, PTEN, and TCF3 in the relapse samples. The average number of CNAs at diagnosis and relapse was the same. The combination of both CDK2NA and IKZF1 deletions (26%) correlated with a significantly worse OS than having only one or neither of these deletions. Age was the only other covariate significant in univariate analyses for OS, yet IKZF1/CDKN2Aco deletion remained significant in multivariate analysis adjusting for age. When identified in diagnostic samples, co deletion of CDKN2A/IKZF1 is a negative prognostic marker in adult B ALL.
39 Seventy patients had a single relapse, 15 cases had 2 relapses, and 8 cases developed a second tumor of different lineage (B cell lymphoma, chronic myeloid leukemia (n=1 each) and acute myeloid leukemia (n=6)). Diagnosis and relapse samples were studied using Affymetrix SNP 6.0 microarrays and whole genome or whole exome sequencing. The number of CNAs did not differ significantly between diagnosis (with a median of 9) and relapse (compared to a median of 10). The median number of mutations was 12 (range 0 70) at diagnosis (n=91), 21 (range 0 858) at relapse. The most frequently mutated genes were NOTCH1 (n=33), NRAS (n=24), CREBBP (n=20) and KRAS (n=16). Clonal evolution analyses showed multiple patterns of evolution. Comprehensive germline analyses are underway.
PAX5-JAK2 fusion in acute lymphoblastic leukaemia. Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne
PAX5-JAK2 fusion in acute lymphoblastic leukaemia Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne Case 12-year-old girl Diagnosed with BCP ALL in November 2015 Presenting WCC 35x10
More informationPh-like (BCR/ABL1-like): un apporoccio baato sul target molecolare
Ph-like (BCR/ABL1-like): un apporoccio baato sul target molecolare Sabina Chiaretti, MD PhD LE SFIDE DELLA MEDICINA DI PRECISIONE IN EMATOLOGIA Bologna 28 Giugno, 2018 Topics: BCR/ABL1-like and other subgroups
More informationCase 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX
Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME
More informationRisk Stratification in Childhood Leukemia
Risk Stratification in Childhood Leukemia Why is risk stratification important? Toxicities Deepa Bhojwani, MD May 11, 2018 To determine intensity of therapy - When to intensify therapy - When to de-intensify
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationCelebrating 20 years of the Database Joint UKCCG and CHO Annual Conference. 22 nd -23 rd March 2012 Newcastle upon Tyne
Celebrating 20 years of the Database Joint UKCCG and CHO Annual Conference 22 nd -23 rd March 2012 Newcastle upon Tyne The following years. FISH and genomics Christine Harrison Chair, UK Cancer Cytogenetics
More informationBCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures
Published Ahead of Print on June 4, 2015, as doi:10.3324/haematol.2015.124941. Copyright 2015 Ferrata Storti Foundation. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationPh-like acute lymphoblastic leukemia
OPTIMIZING TREATMENTS FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: WHAT IT TAKES TO MOVE THE NEEDLE Ph-like acute lymphoblastic leukemia Thai Hoa Tran 1 and Mignon L. Loh 1,2 1 Helen Diller Family Comprehensive
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationApplication of Whole Genome Microarrays in Cancer: You should be doing this test!!
Application of Whole Genome Microarrays in Cancer: You should be doing this test!! Daynna Wolff, Ph.D. Director, Cytogenetics and Genomics Disclosures Clinical Laboratory Director and Employee, Medical
More informationSALSA MLPA probemix P383-A1 T-ALL Lot A
SALSA MLPA probemix P383-A1 T-ALL Lot A1-0213. T-lineage acute lymphoblastic leukaemia (T-ALL) is a clonal malignant disorder of immature T-cells, which accounts for about 15% of paediatric and 25% of
More informationADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW
ADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW Danièle SOMMELET European Scientific Seminar Luxemburg, 3.11.2009 1 Definition of acute leukemias Malignant process coming from lymphoid (85 %)
More informationRelapse Cytogenetics Overview of ALLR3 genetics Introduction to the IntReALL trial. Anthony V Moorman Leukaemia Research Cytogenetics Group
Relapse Cytogenetics Overview of ALLR3 genetics Introduction to the IntReALL trial Anthony V Moorman Leukaemia Research Cytogenetics Group Overview of ALLR3 Parker et al, Lancet 2010; 376: 2009 17 Mitoxantrone
More informationHandout for lecture on lymphoblastic neoplasms presented by Rob McKenna
Handout for lecture on lymphoblastic neoplasms presented by Rob McKenna The following slides represent a near final version of the presentation that will be given in Maui, January 23,2018. Minor changes
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationAddressing the challenges of genomic characterization of hematologic malignancies using microarrays
Addressing the challenges of genomic characterization of hematologic malignancies using microarrays Sarah South, PhD, FACMG Medical Director, ARUP Laboratories Department of Pediatrics and Pathology University
More informationGenomic Characterization of Acute Leukemias
Review Received: November 3, 2013 Accepted: April 10, 2014 Published online: June 20, 2014 Genomic Characterization of Acute Leukemias Sabina Chiaretti Valentina Gianfelici Giulia Ceglie Robin Foà Division
More informationTCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations.
Supplementary Figure 1 TCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations. The CpG motifs closest to the breakpoints are highlighted in red boxes and the
More informationHD-SNP Microarray Analysis of the Study 9 High Risk ALL Patients -
HD-SNP Microarray Analysis of the Study 9 High Risk ALL Patients - Increased Yield of Important Prognostic Information Nadine K Berry 1,2,4, Rodney J. Scott 1,4, Rosemary Sutton 5, Toby N Trahair 5, Philip
More informationETP - Acute Lymphoblastic Leukaemia
ETP - Acute Lymphoblastic Leukaemia Dr Sally Campbell - Royal Children s Hospital Melbourne 24 February 2017 T-ALL 12-15% of all newly diagnosed ALL cases in pediatrics are T-ALL T-ALL behaves differently
More informationDR. MULLIGHAN HAS NOTHING TO DISCLOSE
Advances in the genetics of B-progenitor acute lymphoblastic leukemia Charles Mullighan Member, Department of Pathology St Jude Children s Research Hospital Society for Hematopathology Companion Meeting
More informationCLINICAL UTILITY OF INTEGRATED GENOMIC PROFILING IN PEDIATRIC LEUKEMIA
CLINICAL UTILITY OF INTEGRATED GENOMIC PROFILING IN PEDIATRIC LEUKEMIA FUMIN LIN, Ph.D. LINF1@EMAIL.CHOP.EDU CANCER GENOMIC DIAGNOSTIC LABORATORY DIVISION OF GENOMIC DIAGNOSTICS 1 PEDIATRIC LEUKEMIA Common
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More information35 th UKCCG Meeting. Joint UKCCG and CHO Annual Conference. 9 th 10 th April 2013 Newcastle upon Tyne
35 th UKCCG Meeting Joint UKCCG and CHO Annual Conference 9 th 10 th April 2013 Newcastle upon Tyne Welcome! 35 th UKCCG Meeting Joint UK Cancer Cytogenetics Group and Centre Haemato-Oncology Annual Conference
More informationNature Genetics: doi: /ng Supplementary Figure 1. HOX fusions enhance self-renewal capacity.
Supplementary Figure 1 HOX fusions enhance self-renewal capacity. Mouse bone marrow was transduced with a retrovirus carrying one of three HOX fusion genes or the empty mcherry reporter construct as described
More informationPhiladelphia-like B-cell precursor acute lymphoblastic leukemia (Ph-like
ARTICLE Acute Lymphoblastic Leukemia EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Adults with Philadelphia chromosome like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations,
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091534 Age 36 Years Gender Female 1/9/2017 120000AM 1/9/2017 105316AM 2/9/2017 104147AM Ref By Final LEUKEMIA GENETIC ROFILE ANY SIX MARKERS, CR QUALITATIVE AML ETO
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis
More informationTreatment of High-risk Acute Lymphoblastic Leukemia With Precision Medicine
Treatment of High-risk Acute Lymphoblastic Leukemia With Precision Medicine Minimal Residual Leukemia Level: Independent Prognostic Indicator Leukemic cell Tumor burden Growth potential Drug resistance
More informationControversies in Hematology: Case-Based Discussion. Acute leukemia in Adolescents and Young adults October 2018, Chiang Mai Thailand
Controversies in Hematology: Case-Based Discussion Acute leukemia in Adolescents and Young adults 25-26 October 2018, Chiang Mai Thailand Associate Prof. Adisak Tantiworawit, MD Division of Hematology,
More informationJordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationLymphoblastic Leukemia / Lymphoma
1 5014 - Topics in Pediatric Hematopathology: Acute Lymphoblastic Leukemia, Including Changes in the Revised WHO Classification, and Unusual Pediatric Myeloid Neoplasms Robert W. McKenna, MD MASCP * Elizabeth
More informationA pediatric patient with acute leukemia of ambiguous lineage with a NUP98-NSD1 rearrangement SH
A pediatric patient with acute leukemia of ambiguous lineage with a NUP98NSD1 rearrangement SH20170203 Rebecca LeemanNeill, Ronald Rice, Anita Malek, Patricia Raciti, Susan Hsiao, Mahesh Mansukhani, Bachir
More informationDevelopment of Precision Medicine Therapies for Pediatric Acute Lymphoblastic Leukemia Korean Society of Hematology Meeting March 31, 2018
Development of Precision Medicine Therapies for Pediatric Acute Lymphoblastic Leukemia Korean Society of Hematology Meeting March 31, 2018 Stephen P. Hunger, M.D. Chief, Division of Pediatric Oncology
More informationPatricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope
Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures
More informationCase Report RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia
Case Reports in Hematology Volume 2015, Article ID 353247, 6 pages http://dx.doi.org/10.1155/2015/353247 Case Report RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Roberts KG, Li Y, Payne Turner D, et al. Targetable kinase-activating
More informationGenomic analysis of childhood High grade glial (HGG) brain tumors
Genomic analysis of childhood High grade glial (HGG) brain tumors Linda D Cooley Children s Mercy, Kansas City The Children s Mercy Hospital, 2017 Genomic analysis of childhood High grade glial (HGG) brain
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More informationFunctional characterization and targeting of CRLF2 gene alerations in pediatric High Risk Acute Lymphoblastic Leukemia
PhD Program in Molecular and Translational Medicine DIMET (XXVII cycle, year 2013-2014) University of Milano-Bicocca Department of Biotechnologies and Biosciences Functional characterization and targeting
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationTargetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Original Article Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia K.G. Roberts, Y. Li, D. Payne Turner, R.C. Harvey, Y.-L. Yang, D. Pei, K. McCastlain, L. Ding, C. Lu, G. Song,
More informationSUPPLEMENTARY INFORMATION
Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics
More informationNature Medicine: doi: /nm.4439
Figure S1. Overview of the variant calling and verification process. This figure expands on Fig. 1c with details of verified variants identification in 547 additional validation samples. Somatic variants
More informationWHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities Robert W. McKenna, M.D. 1/2009 WHO Classification of Myeloid Neoplasms (4th Edition)--2008 Incorporates new information that
More informationIllumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
More informationNext Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory
Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular
More informationCase #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...
Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR
More informationMolecular genetics of B-precursor acute lymphoblastic leukemia
Review series Molecular genetics of B-precursor acute lymphoblastic leukemia Charles G. Mullighan Department of Pathology, St. Jude Children s Research Hospital, Memphis, Tennessee, USA. B-precursor acute
More informationNew Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update
Review New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update Adrián Montaño 1,, Maribel Forero-Castro 2,, Darnel Marchena-Mendoza 1,2, Rocío Benito
More informationNews Release. Title Integrated molecular profiling of juvenile myelomonocytic leukemia
News Release Title Integrated molecular profiling of juvenile myelomonocytic leukemia Key Points We identified ALK/ROS1 tyrosine kinase fusions (DCTN1-ALK, RANBP2-ALK, and TBL1XR1-ROS1) in patients with
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationGenome sequencing of lymphoid malignancies
From bloodjournal.hematologylibrary.org by RAUL RIBEIRO on December 30, 2013. For personal use only. Charles G. Mullighan 2013 122: 3899-3907 Prepublished online September 16, 2013; doi:10.1182/blood-2013-08-460311
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationMixed Phenotype Acute Leukemias
Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based
More informationMolecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA
Molecular Genetics of Paediatric Tumours Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA Financial Disclosure NanoString - conference costs for
More informationKrishna Reddy CH and Ashwin Dalal. Diagnostics Division, Centre for DNA Fingerprinting and Diagnostics, Hyderabad
Clinical Cytogenetics in the Diagnosis and Prognosis of Leukemias Krishna Reddy CH and Ashwin Dalal Diagnostics Division, Centre for DNA Fingerprinting and Diagnostics, Hyderabad Email: krishnareddy.chr@gmail.com
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationNUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia
Case 0094 NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Jessica Snider, MD Medical University of South Carolina Case Report - 64 year old Caucasian Male Past Medical History Osteoarthritis
More informationDo acgh analysis have a place in routine cytogenetic workup in leukemia/cancer? - A single institution experience. Cambridge, April 9 th 2013
Do acgh analysis have a place in routine cytogenetic workup in leukemia/cancer? - A single institution experience. Cambridge, April 9 th 2013 Aarhus University Hospital Eigil Kjeldsen, Cancercytogenetic
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationWhole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute
Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes
More informationCase #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed
Case #1 65 yo man with no prior history presented with leukocytosis and circulating blasts: WBC 187.4K/uL ; Hgb 10.0gm/dL; Platelet 68K/uL Neutrophil % 25.0% Lymphocyte % 38.0% Monocyte % 12.0% Metamyelocyte
More informationTemplate for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms
Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Version: MPNBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is NOT required for accreditation
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationHeme fusion assay. Valentina Nardi, MD Assistant pathologist Massachusetts General Hospital Assistant Professor Harvard Medical School
Heme fusion assay Valentina Nardi, MD Assistant pathologist Massachusetts General Hospital Assistant Professor Harvard Medical School No personal disclosures/conflicts of interest Kinase fusions in solid
More informationMyeloma Genetics what do we know and where are we going?
in partnership with Myeloma Genetics what do we know and where are we going? Dr Brian Walker Thames Valley Cancer Network 14 th September 2015 Making the discoveries that defeat cancer Myeloma Genome:
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationInitial Diagnostic Workup of Acute Leukemia
Initial Diagnostic Workup of Acute Leukemia Guideline from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) Publication: Archives of Pathology and Laboratory Medicine
More informationTargeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders
Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders Richard D. Press, MD, PhD Dept of Pathology Knight Cancer Institute Knight Diagnostic Labs Oregon Health & Science University
More informationPediatric Treatment Approaches for Adolescent and Young Adult Acute Lymphoblastic Leukemia
Pediatric Treatment Approaches for Adolescent and Young Adult Acute Lymphoblastic Leukemia 2017 Texas Adolescent and Young Adult (TAYA) Oncology Conference Elizabeth Raetz, MD Acute Lymphoblastic Leukemia
More informationWest Midlands Regional Genetics Laboratory
West Midlands Regional Genetics Laboratory Haemato-oncology service update letter October 2017 Dear colleagues, We are writing to outline the latest developments to our service, aiming to support the management
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationGenomic complexity and arrays in CLL. Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy
Genomic complexity and arrays in CLL Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy Clinical relevance of genomic complexity (GC) in CLL GC has been identified as a critical negative
More informationSchool of Pathology and Laboratory Medicine: Current and New Research Interests
School of Pathology and Laboratory Medicine: Current and New Research Interests W/Professor Wendy Erber Current Research Interests Viral immunology and immunogenetics Bone pathology and cell signalling
More informationModule 3: Pathway and Drug Development
Module 3: Pathway and Drug Development Table of Contents 1.1 Getting Started... 6 1.2 Identifying a Dasatinib sensitive cancer signature... 7 1.2.1 Identifying and validating a Dasatinib Signature... 7
More informationpatients in the era of
Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.
More informationTreatment Manual Of Acute Leukemia By Ward D Merkeley
Treatment Manual Of Acute Leukemia By Ward D Merkeley If searched for the ebook Treatment manual of acute leukemia by Ward D Merkeley in pdf format, then you have come on to the correct website. We presented
More informationEpigenetic programming in chronic lymphocytic leukemia
Epigenetic programming in chronic lymphocytic leukemia Christopher Oakes 10 th Canadian CLL Research Meeting September 18-19 th, 2014 Epigenetics and DNA methylation programming in normal and tumor cells:
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationTEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
More informationNature Genetics: doi: /ng Supplementary Figure 1. Somatic coding mutations identified by WES/WGS for 83 ATL cases.
Supplementary Figure 1 Somatic coding mutations identified by WES/WGS for 83 ATL cases. (a) The percentage of targeted bases covered by at least 2, 10, 20 and 30 sequencing reads (top) and average read
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationIdentifying therapeutic targets by elucidating signaling pathways in pediatric lymphoid leukemias van der Sligte, Naomi Eline
University of Groningen Identifying therapeutic targets by elucidating signaling pathways in pediatric lymphoid leukemias van der Sligte, Naomi Eline IMPORTANT NOTE: You are advised to consult the publisher's
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More information